

US-China collaboration to deliver multiplexed solutions for mRNA vaccine and cell & gene therapy

07 June 2024 | News

Partnership addresses biopharmaceutical industry's urgent need for improved in-process and QC testing tools for these rapidly evolving application fields



US-based InDevR, Inc., a leading provider of analytical tools for vaccine quality control and testing, has teamed up with Sino Biological, Inc., a biotechnological firm listed on the Shenzhen stock exchange, which specialises in biological research reagents and related technical services.

This partnership aims to speed up the development of multiplex assays for a variety of applications in vaccine production, mRNA therapies, and cell and gene therapy.

As part of the collaboration, Sino Biological's comprehensive range of high-quality antibodies, antigens, and other reagents will be made available for use on InDevR's VaxArray Platform. This platform is widely used by biopharmaceutical companies globally for its ability to perform multiplex assays, which help simplify, standardise, and accelerate the development, optimisation, and scaling of new vaccine formulations.

The alliance intends to develop advanced analytical tools to support breakthroughs in mRNA vaccine technology, vaccine development, and the fast-growing field of cell and gene therapy.